15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Halozyme Therapeutics Inc, 6 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $56.00 to $95.00, a moderate spread. The average target of $81.70 sits 2% below the current $83.39. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.19 next quarter toward $9.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy660%
Hold440%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Halozyme Therapeutics Inc.
As of Jul, 6 of 10 firms rate HALO a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HALO EPS & revenue forecast
EPS · NEXT QUARTER
$2.19
Range $2.11 – $2.30 · 7 analysts · +27% YoY
Next period, 7 analysts expect Halozyme Therapeutics Inc to earn $2.19 a share (range $2.11 – $2.30), versus $1.72 a year earlier. Full-year consensus is $8.11, growing to $9.91 the year after.
REVENUE · NEXT QUARTER
$465.6M
Range $445.0M – $491.0M · 7 analysts · +31% YoY
Revenue is expected to reach $465.6M (range $445.0M – $491.0M), +31.4% year-over-year. Full-year consensus is $1.8B, rising to $2.0B next year.
Top analysts covering Halozyme Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HALO.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$92.00+10.3% to target
Overall win rate
57%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #64
Hold
$65.00-22.1% to target
Overall win rate
52%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$95.00+13.9% to target
Overall win rate
34%
+ Follow
#4
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$90.00+7.9% to target
Overall win rate
39%
+ Follow
#5
VP
Vikram Purohit
Morgan Stanley
Buy
$93.00+11.5% to target
Coverage
—
+ Follow
HALO stock forecast FAQ
What is HALO's average 12-month price target?+
The 10 analysts with a live target average $81.70 for Halozyme Therapeutics Inc over the next 12 months, ranging from a $95.00 high to a $56.00 low.
Is HALO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 6 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HALO?+
The Street-high target is $95.00 (HC Wainwright & Co.), and the Street-low is $56.00 (Goldman Sachs). The average of all 10 active targets is $81.70.
How many Wall Street analysts cover HALO?+
10 analysts have an active rating on Halozyme Therapeutics Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering HALO?+
Among analysts who currently cover HALO, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $92.00 target.
What is Halozyme Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $2.19 per share (range $2.11 – $2.30) across 7 analysts. Full-year EPS is projected at $8.11, rising to $9.91 the following year.
How much revenue is Halozyme Therapeutics Inc expected to report next quarter?+
Consensus revenue is $465.6M (range $445.0M – $491.0M). Full-year revenue is projected at $1.8B, growing to $2.0B next year.
Have analysts been upgrading or downgrading HALO lately?+
As of Jul, 6 of 10 firms rate HALO a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HALO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
